Replimune Group, Inc. (REPL) Stock

Replimune Group, Inc. (REPL) is a Healthcare stock trading at $10.15 (as of 2026-06-18), with a market capitalization of $717.56M and a trailing P/E of -2.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Replimune Group, Inc. is a biotechnology company developing oncolytic immuno-gene therapies for cancer. Using its proprietary immunotherapy platform, it designs and advances product candidates such as RP1, RP2, and RP3, which are in clinical trials across multiple solid tumor types and specific indications.

Valuation — source: SEC EDGAR (first-party)
Price$10.15
Market Cap$717.56M
P/E Ratio-2.5
EV / EBITDA-2.0
Price / Book3.41
DCF Value (model)$-43.07
DCF Upside vs Price-524.3%
Profitability & Growth — source: SEC EDGAR
Return on Equity-149.5%
Debt / Equity0.23
Current Ratio5.60
Valuation vs Sector & Industry
Stock P/E-2.5
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-112.1%
vs Industry-114.8%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderBAKER BROS. ADVISORS LP ($84.50M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSushil Patel
Employees479
CountryUS
IPO Date2018-07-20

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • MapLight Therapeutics, Inc. (MPLT)
  • Anavex Life Sciences Corp. (AVXL)
  • Esperion Therapeutics, Inc. (ESPR)
  • Jade Biosciences, Inc. (JBIO)
  • Arvinas, Inc. (ARVN)
  • Fulcrum Therapeutics, Inc. (FULC)
  • Annexon, Inc. (ANNX)
  • REGENXBIO Inc. (RGNX)
REPL earnings history · REPL institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.